Royal Bank of Canada Reiterates “Outperform” Rating for Illumina (NASDAQ:ILMN)

Royal Bank of Canada reaffirmed their outperform rating on shares of Illumina (NASDAQ:ILMNFree Report) in a research report sent to investors on Friday morning, Benzinga reports. They currently have a $258.00 target price on the life sciences company’s stock.

Other research analysts also recently issued research reports about the stock. Citigroup upgraded shares of Illumina from a sell rating to a neutral rating and boosted their price target for the stock from $85.00 to $120.00 in a research report on Monday, December 11th. Stephens began coverage on shares of Illumina in a research report on Thursday, December 14th. They issued an overweight rating and a $170.00 price target on the stock. TD Cowen downgraded shares of Illumina from an outperform rating to a market perform rating and set a $144.00 price target on the stock. in a research report on Thursday, January 4th. Bank of America downgraded shares of Illumina from a neutral rating to an underperform rating and dropped their price target for the stock from $140.00 to $100.00 in a research report on Tuesday, December 12th. Finally, Scotiabank upgraded shares of Illumina from a sector perform rating to a sector outperform rating and set a $185.00 price target on the stock in a research report on Monday, December 18th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Illumina has a consensus rating of Hold and a consensus target price of $166.95.

Read Our Latest Research Report on Illumina

Illumina Trading Up 1.5 %

ILMN opened at $139.96 on Friday. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $238.55. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a market capitalization of $22.23 billion, a price-to-earnings ratio of -19.07, a PEG ratio of 25.05 and a beta of 1.22. The company’s 50 day moving average price is $135.76 and its two-hundred day moving average price is $137.24.

Illumina (NASDAQ:ILMNGet Free Report) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the firm posted $0.14 EPS. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, research analysts predict that Illumina will post 1.03 earnings per share for the current year.

Institutional Trading of Illumina

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Illumina by 15.0% during the 3rd quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after purchasing an additional 2,336,935 shares in the last quarter. Polen Capital Management LLC grew its stake in shares of Illumina by 0.6% in the 3rd quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company’s stock worth $703,782,000 after acquiring an additional 29,153 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Illumina by 5.5% in the 3rd quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company’s stock worth $550,212,000 after acquiring an additional 208,267 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Illumina by 6.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock worth $500,926,000 after acquiring an additional 225,074 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Illumina by 18.6% in the 2nd quarter. Geode Capital Management LLC now owns 3,473,112 shares of the life sciences company’s stock worth $649,525,000 after acquiring an additional 544,786 shares in the last quarter. Institutional investors own 92.17% of the company’s stock.

Illumina Company Profile

(Get Free Report)

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Further Reading

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.